2021 ACC Annual Meeting*

Download All
May 15-17, 2021; Virtual
Review the latest data in managing heart failure with Capsule Summaries and expert-authored commentaries covering key studies from ACC 2021.

Capsule Summary Slidesets

Reduction in CV events seen with fish oil derivative in REDUCE-IT.

Released: June 25, 2021

The use of empagliflozin in routine care of East Asian patients with type 2 diabetes reduced risk of hospitalization for heart failure, cardiovascular outcomes, and all-cause mortality vs DPP-4 inhibitors.

Released: June 30, 2021

Addition of cardiac rehabilitation to usual care significantly improved QoL, functional capacity, and diastolic function in patients with HFpEF.

Released: June 30, 2021

In patients with heart failure, sGC stimulators reduced risk of a combined endpoint including cardiovascular death and hospitalization for heart failure in individuals with reduced ejection fraction but had no benefit in those with preserved ejection fraction.

Released: June 28, 2021

Data from the Swedish HF Registry show that the effect of beta-blockers in patients with HF With Preserved EF is unclear.

Released: June 28, 2021

In meta-analysis of 62 placebo-controlled RCTs, SGLT2 inhibitors were associated with increased risk of infection and diabetic ketoacidosis but showed similar rates of hypoglycemia, bone fracture, and amputations as placebo.

Released: June 29, 2021

In meta-analysis of 15 randomized, placebo-controlled clinical trials, SGLT2 inhibitors reduced risk of all-cause and CV mortality and risk of composite heart failure endpoint in key patient subgroups.

Released: July 1, 2021

In meta-analysis of 8 randomized placebo-controlled clinical trials, addition of oral sGC stimulators to guideline-directed medical therapy for heart failure reduced risk of hospitalization for heart failure vs placebo; net adverse events not significantly increased over placebo.

Released: June 29, 2021
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue